Diagnos $ADK #DGNOF Signs Memorandum of Understanding with #Essilor International

Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of critical health issues, is pleased to announce that it has entered into a Memorandum of Understanding (MoU) with the Instruments division of Essilor International, a subsidiary of EssilorLuxottica. Essilor International is the world’s leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses and diagnostic ophthalmic instruments.

 The MoU is non-binding and forms the basis of a potential distribution agreement with Essilor International for DIAGNOS’ CARA platform for the AI-enhanced analysis of wide-field retinal images, as well as of certain specified future developments of the CARA platform for a variety of applications.

 DIAGNOS has under development multiple new applications involving AI-enhanced retinal imaging to address a growing need for general purpose pathology identification. In addition to localized retinal pathology, such as macular degeneration and glaucoma, certain retinal pathologies are also known indicators of various systemic disorders, including cardiovascular and diabetic diseases. On July 20th 2021, DIAGNOS announced a clinical trial with CommonSpirit Health Research Institute in the USA for the early detection of stroke through the inspection and analysis of the retina.

 “DIAGNOS is focused on its commercialization strategy and pursuing opportunities with potential partners. We are very pleased that our AI-based technology has attracted the attention of global eyecare sector leaders such as Essilor International and we are looking forward to our discussions with respect to a mutually beneficial potential worldwide distribution agreement. At the same time, DIAGNOS continues to invest in Research and Development, furthering the creation of our intellectual property by partnering with Quebec government programs and local university (École de Technologie Supérieure) to ensure that we stay ahead of our competition worldwide,” said Mr. André Larente, President of DIAGNOS

Leave a Reply

Your email address will not be published. Required fields are marked *